Hepatitis A vaccination

References

• Feinstone SM, Kapikian AZ, Purcell RH. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science. 1973;182(4116):1026–28. doi:10.1126/science.182.4116.1026.
   PubMed Web of Science ®Google Scholar
• Cooksley WG. What did we learn from the Shanghai hepatitis A epidemic? J Viral Hepat. 2000;7 Suppl 1:1–3. doi:10.1046/j.1365-2893.2000.00021.x.
   PubMedGoogle Scholar
• Jacobsen KH. Globalization and the changing epidemiology of hepatitis A virus. Cold Spring Harb Perspect Med. 2018;8(10):a031716. doi:10.1101/cshperspect.a031716.
   PubMed Web of Science ®Google Scholar
• Gripenberg M, Aloysia D’Cor N, L’Azou M, Marsh G, Druelles S, Nealon J. Changing sero-epidemiology of hepatitis A in Asia Pacific countries: A systematic review. Int J Infect Dis. 2018;68:13–17. doi:10.1016/j.ijid.2017.12.021.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen Y, Xie S, Lv H. Changing epidemiological characteristics of hepatitis A in Zhejiang Province, China: increased susceptibility in adults. PLoS One. 2016;11(4):e0153804. doi:10.1371/journal.pone.0153804.
   PubMed Web of Science ®Google Scholar
• Lee HC, Ang LW, Chiew PK, James L, Goh KT. Changing epidemiological patterns of hepatitis A infection in Singapore. Ann Acad Med Singapore. 2011;40:439–47.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis A - fact sheet 2019. 2019 [accessed 2019 Dec 20]. https://www.who.int/news-room/fact-sheets/detail/hepatitis-a.
   Google Scholar
• World Health Organization. Global health sector strategy on viral hepatitis, 2016–2021 Geneva: World Health Organization; 2016 Jun [accessed 2019 Dec 20]. http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=1.
   Google Scholar
• Provost PJ, Bishop RP, Gerety RJ, Hilleman MR, McAleer WJ, Scolnick EM, Stevens CE. New findings in live, attenuated hepatitis A vaccine development. J Med Virol. 1986;20(2):165–75. doi:10.1002/jmv.1890200208.
   PubMed Web of Science ®Google Scholar
• Hilleman MR. Hepatitis and hepatitis A vaccine: a glimpse of history. J Hepatol. 1993;18 Suppl 2:S5–10. doi:10.1016/S0168-8278(05)80370-8.
   PubMed Web of Science ®Google Scholar
• Martin A, Lemon SM. Hepatitis A virus: from discovery to vaccines. Hepatology. 2006;43(2 Suppl 1):S164–72. doi:10.1002/hep.21052.
   PubMed Web of Science ®Google Scholar
• Peetermans J. Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine. 1992;10 Suppl 1:S99–101. doi:10.1016/0264-410X(92)90557-Z.
   PubMed Web of Science ®Google Scholar
• Armstrong ME, Giesa PA, Davide JP, Redner F, Waterbury JA, Rhoad AE, Keys RD, Provost PJ, Lewis JA. Development of the formalin-inactivated hepatitis A vaccine, VAQTATM from the live attenuated virus strain CR326F. J Hepatol. 1993;18 Suppl 2:S20–26. doi:10.1016/S0168-8278(05)80373-3.
   PubMed Web of Science ®Google Scholar
• Vidor E, Fritzell B, Plotkin S. Clinical development of a new inactivated hepatitis A vaccine. Infection. 1996;24(6):447–58. doi:10.1007/BF01713047.
   PubMed Web of Science ®Google Scholar
• Gluck R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ Jr.:. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest. 1992;90(6):2491–95. doi:10.1172/JCI116141.
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Gluck R, Herzog C. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine. 1997;15(11):1209–13. doi:10.1016/S0264-410X(97)00015-7.
   PubMed Web of Science ®Google Scholar
• Cui F, Liang X, Wang F, Zheng H, Hutin YJ, Yang W. Development, production, and postmarketing surveillance of hepatitis A vaccines in China. J Epidemiol. 2014;24(3):169–77. doi:10.2188/jea.JE20130022.
   PubMed Web of Science ®Google Scholar
• Van Hoecke C, Lebacq E, Beran J, Prymula R, Collard F. Concomitant vaccination against hepatitis A and typhoid fever. J Travel Med. 1998;5(3):116–20. doi:10.1111/j.1708-8305.1998.tb00483.x.
   PubMed Web of Science ®Google Scholar
• Bakker M, Bunge EM, Marano C, de Ridder M, De Moerlooze L. Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review. Expert Rev Vaccines. 2016;15(7):829–51. doi:10.1586/14760584.2016.1150182.
   PubMed Web of Science ®Google Scholar
• Shouval D. The immunological basis for immunization series. In: Immunization vaccines and biologicals. Geneva: World Health Organization; 2010. p. 1–39.
   Google Scholar
• Vaccine SotNACoINSUotRUoHA. WHO position paper on hepatitis A vaccines: June 2012-recommendations. Vaccine. 2013;31(2):285–86. doi:10.1016/j.vaccine.2012.10.102.
   PubMed Web of Science ®Google Scholar
• Lolekha S, Pratuangtham S, Punpanich W, Bowonkiratikachorn P, Chimabutra K, Weber F. Immunogenicity and safety of two doses of a paediatric hepatitis A vaccine in thai children: comparison of three vaccination schedules. J Trop Pediatr. 2003;49(6):333–39. doi:10.1093/tropej/49.6.333.
   PubMed Web of Science ®Google Scholar
• Williams JL, Bruden DA, Cagle HH, McMahon BJ, Negus SE, Christensen CJ, Snowball MM, Bulkow LR, Fox-Leyva LK. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine. 2003;21(23):3208–11. doi:10.1016/S0264-410X(03)00250-0.
   PubMed Web of Science ®Google Scholar
• immigrantNelson NP, Link-Gelles R, Hofmeister MG, Romero JR, Moore KL, Ward JW, Schillie SF. Update: recommendations of the Advisory Committee on immunization practices for use of hepatitis A vaccine for postexposure prophylaxis and for preexposure prophylaxis for international travel. MMWR Morb Mortal Wkly Rep. 2018;67(43):1216–20. doi:10.15585/mmwr.mm6743a5.
   PubMed Web of Science ®Google Scholar
• Henry B, Baclic O, National Advisory Committee on I. Summary of the National Advisory Committee on Immunization (NACI) statement update on the recommended use of hepatitis A vaccine. Can Commun Dis Rep. 2016;42(9):193–94. doi:10.14745/ccdr.v42i09a07.
   PubMedGoogle Scholar
• Bienzle U, Bock HL, Kruppenbacher JP, Hofmann F, Vogel GE, Clemens R. Immunogenicity of an inactivated hepatitis A vaccine administered according to two different schedules and the interference of other “travellers” vaccines with the immune response. Vaccine. 1996;14(6):501–05. doi:10.1016/0264-410X(95)00224-O.
   PubMed Web of Science ®Google Scholar
• Zhang Z-L, Zhu X-J, Wang X, Liang M, Sun J, Liu Y, Gao Z-G, Wu J-Y, Dong X-J, Liu R-K, et al. Interchangeability and tolerability of two inactivated hepatitis A vaccines in Chinese children. Vaccine. 2012;30(27):4028–33. doi:10.1016/j.vaccine.2012.04.038.
   PubMed Web of Science ®Google Scholar
• Abarca K, Ibanez I, Perret C, Vial P, Zinsou J-A. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. Int J Infect Dis. 2008;12(3):270–77. doi:10.1016/j.ijid.2007.08.006.
   PubMed Web of Science ®Google Scholar
• Soysal A, Gokce I, Pehlivan T, Bakir M. Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in Turkey. Eur J Pediatr. 2007;166(6):533–39. doi:10.1007/s00431-007-0432-0.
   PubMed Web of Science ®Google Scholar
• Berger R, Just M, Althaus B. Time course of hepatitis A antibody production after active, passive and active/passive immunisation: the results are highly dependent on the antibody test system used. J Virol Methods. 1993;43(3):287–97. doi:10.1016/0166-0934(93)90147-J.
   PubMed Web of Science ®Google Scholar
• Askling HH, Rombo L, van Vollenhoven R, Hallen I, Thorner Å, Nordin M, Herzog C, Kantele A. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Travel Med Infect Dis. 2014;12(2):134–42. doi:10.1016/j.tmaid.2014.01.005.
   PubMed Web of Science ®Google Scholar
• hShouval D. Immunization against hepatitis A. Cold Spring Harb Perspect Med. 2019;9(2).
   Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–65. doi:10.1128/CVI.00131-10.
   PubMed Web of Science ®Google Scholar
• Purcell RH, D’Hondt E, Bradbury R, Emerson SU, Govindarahan S, Binn L. Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees. Vaccine. 1992;10 Suppl 1:S148–51. doi:10.1016/0264-410X(92)90572-2.
   PubMed Web of Science ®Google Scholar
• Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, Miller W, Shouval D, Wiens B, Calandra G, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med. 1992;327(7):453–57. doi:10.1056/NEJM199208133270702.
   PubMed Web of Science ®Google Scholar
• Robbins DJ, Krater J, Kiang W, Alcalde X, Helgesen S, Carlos J, Mimms L. Detection of total antibody against hepatitis A virus by an automated microparticle enzyme immunoassay. J Virol Methods. 1991;32(2–3):255–63. doi:10.1016/0166-0934(91)90056-6.
   PubMed Web of Science ®Google Scholar
• Jiang WP, Chen JT, Wang X, Wang YL, Liu Y, Chen WY, Xu WG, Qiu YZ, Yin WD. Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial. Vaccine. 2008;26(18):2297–301. doi:10.1016/j.vaccine.2007.11.008.
   PubMed Web of Science ®Google Scholar
• Li RC, Li Y, Yi N, Huang L, Wan Z, Zhang Y, Rasuli A. An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children and adolescents in China. Pediatr Infect Dis J. 2013;32(2):e77–81. doi:10.1097/INF.0b013e318271c4c3.
   PubMed Web of Science ®Google Scholar
• Zheng H, Chen Y, Wang F, Gong X, Wu Z, Miao N, Zhang X, Li H, Chen C, Hou X, et al. Comparing live attenuated and inactivated hepatitis A vaccines: an immunogenicity study after one single dose. Vaccine. 2011;29(48):9098–103. doi:10.1016/j.vaccine.2011.08.078.
   PubMed Web of Science ®Google Scholar
• Hong SS, Choi UY, Ma SH, Lee SY, Han SB, Kim K-H, Kang JH, Kim J-H. Comparison of the immunogenicity and safety of 3 inactivated hepatitis A vaccines in Korean children aged 12 to 18 months: an open-label, randomized, prospective, multicenter study. Medicine. 2019;98(6):e14364. doi:10.1097/MD.0000000000014364.
   PubMed Web of Science ®Google Scholar
• Jain H, Kumavat V, Singh T, Versteilen A, Sarnecki M. Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India. Hum Vaccin Immunother. 2014;10(7):2089–97. doi:10.4161/hv.28631.
   PubMed Web of Science ®Google Scholar
• Liu X-E, Chen H-Y, Liao Z, Zhou Y, Wen H, Peng S, Liu Y, Li R, Li J, Zhuang H. Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines among young adults: a 3-year follow-up study. J Infect Dis. 2015;212(8):1232–36. doi:10.1093/infdis/jiv213.
   PubMed Web of Science ®Google Scholar
• Ma F, Yang J, Kang G, Sun Q, Lu P, Zhao Y, Wang Z, Luo J, Wang Z. Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study. Clin Microbiol Infect. 2016;22(9):811.e9–15. doi:10.1016/j.cmi.2016.06.004.
   PubMed Web of Science ®Google Scholar
• Liu H-F, Zhang X-J, Zhang J-L, Hao Z-Y, Zhang Z-Y, Ma J-C, Chen J-C, Chu J, Wang X-Y, Xu Z-Y. [The immunological effects of three doses of a live attenuated hepatitis A vaccine (H2 strain) in 8 years]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2009;23:180–81.
   PubMedGoogle Scholar
• Abarca K, Ibanez I, de la Fuente P, Cerda L, Bergeret J, Frosner G, Ibarra H. Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1–16 years. Vaccine. 2011;29(48):8855–62. doi:10.1016/j.vaccine.2011.09.095.
   PubMed Web of Science ®Google Scholar
• Garcia Garrido HM, Veurink AM, Leeflang M, Spijker R, Goorhuis A, Grobusch MP. Hepatitis A vaccine immunogenicity in patients using immunosuppressive drugs: a systematic review and meta-analysis. Travel Med Infect Dis. 2019;101479.
   PubMed Web of Science ®Google Scholar
• Lin K-Y, Chen G-J, Lee Y-L, Huang Y-C, Cheng A, Sun H-Y, Chang S-Y, Liu C-E, Hung C-C. Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: a review. World J Gastroenterol. 2017;23(20):3589–606. doi:10.3748/wjg.v23.i20.3589.
   PubMed Web of Science ®Google Scholar
• Phung B-C, Launay O. Vaccination against viral hepatitis of HIV-1 infected patients. Hum Vaccin Immunother. 2012;8(5):554–59. doi:10.4161/hv.19105.
   PubMed Web of Science ®Google Scholar
• Jimenez HR, Hallit RR, Debari VA, Slim J. Hepatitis A vaccine response in HIV-infected patients: are TWINRIX® and HAVRIX® interchangeable? Vaccine. 2013;31(9):1328–33. doi:10.1016/j.vaccine.2012.12.045.
   PubMed Web of Science ®Google Scholar
• Jeon HJ, Ro H, Jeong JC, Koo TY, Han M, Min S-I, Oh K-H, Ha J, Ahn C, Yang J. Efficacy and safety of hepatitis A vaccination in kidney transplant recipients. Transpl Infect Dis. 2014;16(3):511–15. doi:10.1111/tid.12217.
   PubMed Web of Science ®Google Scholar
• Launay O, Grabar S, Gordien E, Desaint C, Jegou D, Abad S, Girard P-M, Belarbi L, Guerin C, Dimet J, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr. 2008;49(3):272–75. doi:10.1097/QAI.0b013e318183a9c0.
   PubMed Web of Science ®Google Scholar
• Rosdahl A, Herzog C, Frosner G, Noren T, Rombo L, Askling HH. An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression – A prospective, open-label, multi-center study. Travel Med Infect Dis. 2018;21:43–50. doi:10.1016/j.tmaid.2017.12.004.
   PubMed Web of Science ®Google Scholar
• Maritsi DN, Coffin SE, Argyri I, Vartzelis G, Spyridis N, Tsolia MN. Immunogenicity and safety of the inactivated hepatitis A vaccine in children with juvenile idiopathic arthritis on methotrexate treatment: a matched case-control study. Clin Exp Rheumatol. 2017;35:711–15.
   PubMed Web of Science ®Google Scholar
• Chen G-J, Sun H-Y, Lin K-Y, Cheng A, Huang Y-C, Hsieh S-M, Sheng W-H, Liu W-C, Hung C-C, Chang S-C. Serological responses to revaccination with hepatitis A virus (HAV) vaccines among HIV-positive individuals whose anti-HAV antibody waned after primary vaccination. Liver Int. 2018;38(7):1198–205. doi:10.1111/liv.13665.
   PubMed Web of Science ®Google Scholar
• Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after vaccination with a 2-dose Havrix™ (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine. 2015;33(42):5723–27. doi:10.1016/j.vaccine.2015.07.008.
   PubMed Web of Science ®Google Scholar
• Chappuis F, Farinelli T, Deckx H, Sarnecki M, Go O, Salzgeber Y, Stals C. Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: a 20-year follow-up study. Vaccine. 2017;35(10):1448–54. doi:10.1016/j.vaccine.2017.01.031.
   PubMed Web of Science ®Google Scholar
• Plumb ID, Bulkow LR, Bruce MG, Hennessy TW, Morris J, Rudolph K, Spradling P, Snowball M, McMahon BJ. Persistence of antibody to hepatitis A virus 20 years after receipt of hepatitis A vaccine in Alaska. J Viral Hepat. 2017;24(7):608–12. doi:10.1111/jvh.12676.
   PubMed Web of Science ®Google Scholar
• Uruena A, Gonzalez JE, Rearte A, Perez Carrega ME, Calli R, Pagani MF, Uboldi A, Vicentin R, Caglio P, Canero-Velasco MC, et al. Single-dose universal hepatitis A immunization in one-year-old children in Argentina: high prevalence of protective antibodies up to 9 years after vaccination. Pediatr Infect Dis J. 2016;35(12):1339–42. doi:10.1097/INF.0000000000001322.
   PubMed Web of Science ®Google Scholar
• Zhuang F-C, Mao Z-A, Jiang L-M, Wu J, Chen Y-Q, Jiang Q, Chen N-L, Chai S-A, Mao J-S. [Long-term immunogenicity and effectiveness of live attenuated hepatitis A vaccine (H2-strain)-a study on the result of 15 years’ follow up]. Zhonghua Liu Xing Bing Xue Za Zhi. 2010;31:1332–35.
   PubMedGoogle Scholar
• Zhang Z, Zhu X, Hu Y, Liang M, Sun J, Song Y, Yang Q, Ji H, Zeng G, Song L, et al. Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine. Hum Vaccin Immunother. 2017;13(6):1–6. doi:10.1080/21645515.2016.1278329.
   Web of Science ®Google Scholar
• Zhang YMJ, Xu ZY, et al. Primary research on epidemiological effect of inactivated hepatitis A vaccine. Zhongguo Gonggong Weisheng Xuebao. 1994;13(6):163. In Chinese.
   Google Scholar
• Ma JCZY, Sun YD, et al. Serological effect after vaccination of live attenuated hepatitis A vaccine. Hebei Yixueyuan Xuebao. 1994;15(3):26. In Chinese.
   Google Scholar
• Zhang YLX, Zhao SJ, et al. Study on immunogenicity of live attenuated hepatitis A vaccine (H2 strain). Hebei Yike Daxue Xuebao. 1997;18(4):209–10. In Chinese.
   Google Scholar
• Wang XYMJ, Zhang Y, et al. Immunogenicity and immune persistence of live attenuated hepatitis A vaccines with different dosage. Zhanghua Liu Xing Bing Xue Za Zhi. 2002;22(2):66–68. In Chinese.
   Google Scholar
• Zhao YL, Meng ZD, Xu ZY, Guo JJ, Chai SA, Duo CG, Wang XY, Yao JF, Liu HB, Qi SX, et al. H2 strain attenuated live hepatitis A vaccines: protective efficacy in a hepatitis A outbreak. World J Gastroenterol. 2000;6(6):829–32. doi:10.3748/wjg.v6.i6.829.
   PubMed Web of Science ®Google Scholar
• Minutello M, Zotti C, Orecchia S, Di Martino E, Bastianoni I, Ypma E, Ruggenini Moiraghi A, Podda A. Dose range evaluation of a new inactivated hepatitis A vaccine administered as a single dose followed by a booster. Vaccine. 2000;19(1):10–15. doi:10.1016/S0264-410X(00)00156-0.
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices Centers for Disease C, Prevention. Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2007;56(41):1080–84.
   PubMedGoogle Scholar
• Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, Favorov MO, Margolis HS, Bell BP. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med. 2007;357(17):1685–94. doi:10.1056/NEJMoa070546.
   PubMed Web of Science ®Google Scholar
• Link-Gelles R, Hofmeister MG, Nelson NP. Use of hepatitis A vaccine for post-exposure prophylaxis in individuals over 40 years of age: A systematic review of published studies and recommendations for vaccine use. Vaccine. 2018;36(20):2745–50. doi:10.1016/j.vaccine.2018.04.015.
   PubMed Web of Science ®Google Scholar
• Van Der Meeren O, Crasta P, de Ridder M. A retrospective pooled analysis assessing the effect of age on the immunogenicity of Havrix™ in healthy adults. Hum Vaccin Immunother. 2015;11(7):1729–34. doi:10.1080/21645515.2015.1045167.
   PubMed Web of Science ®Google Scholar
• Piazza M, Safary A, Vegnente A, Soncini R, Pensati P, Sardo M, Orlando R, Tosone G, Picciotto L. Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme. Vaccine. 1999;17(6):585–88. doi:10.1016/S0264-410X(98)00237-0.
   PubMed Web of Science ®Google Scholar
• Dagan R, Amir J, Mijalovsky A, Kalmanovitch I, Bar-Yochai A, Thoelen S, Safary A, Ashkenazi S. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J. 2000;19(11):1045–52. doi:10.1097/00006454-200011000-00004.
   PubMed Web of Science ®Google Scholar
• Letson GW, Shapiro CN, Kuehn D, Gardea C, Welty TK, Krause DS, Lambert SB, Margolis HS. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr. 2004;144(3):327–32. doi:10.1016/j.jpeds.2003.11.030.
   PubMed Web of Science ®Google Scholar
• Karetnyĭ IV, Kuzin S, Sychev AV, Balaian MS. [Transplacental antibodies to hepatitis A virus]. Vopr Virusol. 1988;33:86–88.
   PubMedGoogle Scholar
• McMahon BJ, Williams J, Bulkow L, Snowball M, Wainwright R, Kennedy M, Krause D. Immunogenicity of an inactivated hepatitis A vaccine in Alaska native children and native and non-native adults. J Infect Dis. 1995;171(3):676–79. doi:10.1093/infdis/171.3.676.
   PubMed Web of Science ®Google Scholar
• Newcomer W, Rivin B, Reid R, Moulton LH, Wolff M, Croll J, Johnson C, Brown L, Nalin D, Santosham M. Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children. Pediatr Infect Dis J. 1994;13(7):640–42. doi:10.1097/00006454-199407000-00011.
   PubMed Web of Science ®Google Scholar
• Shi N, Rasuli A, Thollot Y. Safety of two doses of an inactivated hepatitis a vaccine given 6 months apart in healthy toddlers, children, and adolescents aged 12 months to 15 years in China: a phase IV study. Hum Vaccin Immunother. 2019;15(3):748–54. doi:10.1080/21645515.2018.1539600.
   PubMed Web of Science ®Google Scholar
• Liu D, Wu W, Li K, Xu D, Ye J, Li L, Wang H. Surveillance of adverse events following immunization in China: past, present, and future. Vaccine. 2015;33(32):4041–46. doi:10.1016/j.vaccine.2015.04.060.
   PubMed Web of Science ®Google Scholar
• MIANYI. 2018;24(3):299–309, 322. PsoalhAvHsihDLKWWeaAefiiCYY.
   Google Scholar
• Moro PL, Museru OI, Niu M, Lewis P, Broder K. Reports to the Vaccine Adverse Event Reporting System after hepatitis A and hepatitis AB vaccines in pregnant women. Am J Obstet Gynecol. 2014;210(6):561e561–566. doi:10.1016/j.ajog.2013.12.036.
   Web of Science ®Google Scholar
• Mao JS, Dong DX, Zhang HY, Chen NL, Zhang XY, Huang HY, Xie RY, Zhou TJ, Wan ZJ, Wang YZ, et al. Primary study of attenuated live hepatitis A vaccine (H2 strain) in humans. J Infect Dis. 1989;159(4):621–24. doi:10.1093/infdis/159.4.621.
   PubMed Web of Science ®Google Scholar
• Huang X, Cao Y, Tan S. [Horizontal transmission of live attenuated hepatitis A vaccine virus]. Zhonghua Yi Xue Za Zhi. 2001;81:465–67.
   PubMedGoogle Scholar
• Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Suntayakorn S, Suknantapong T, Safary A, Boslego JW. Field efficacy trial of inactivated hepatitis A vaccine among children in Thailand (an extended abstract). Vaccine. 1992;10(Suppl 1):159–62. doi:10.1016/0264-410X(92)90575-5.
   PubMedGoogle Scholar
• Xu Z, Wang X, Li R, Meng Z, Zhang Y, Gong J, Ma J, Li Y, Zhao S, Li Y, et al. [Immunogenicity and efficacy of two live attenuated hepatitis A vaccines (H(2) strains and LA-1 strains)]. Zhonghua Yi Xue Za Zhi. 2002;82(10):678–81.
   PubMedGoogle Scholar
• Whelan J, Sonder GJ, Bovee L, Speksnijder A, van den Hoek A. Evaluation of hepatitis A vaccine in post-exposure prophylaxis, the Netherlands, 2004–2012. PLoS One. 2013;8(10):e78914. doi:10.1371/journal.pone.0078914.
   PubMed Web of Science ®Google Scholar
• Kohl I, Nemecek V, Summerova M, Chlibek R, Nad’ova K, Minarikova O. Long-term protective effect of post-exposure Havrix administration during viral hepatitis Type A outbreaks. Eur J Epidemiol. 2006;21(12):893–99. doi:10.1007/s10654-006-9081-2.
   PubMed Web of Science ®Google Scholar
• Shouval D, Ashur Y, Adler R, Lewis JA, Armstrong ME, Davide JP, McGuire B, Kuter B, Brown L, et al. Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis. Vaccine. 1993;11 Suppl 1:S9–14. doi:10.1016/0264-410X(93)90151-M.
   PubMed Web of Science ®Google Scholar
• Parron I, Planas C, Godoy P, Manzanares-Laya S, Martinez A, Sala MR, Minguell S, Torner N, Jane M, Dominguez A, et al. Effectiveness of hepatitis A vaccination as post-exposure prophylaxis. Hum Vaccin Immunother. 2017;13(2):423–27. doi:10.1080/21645515.2017.1264798.
   PubMed Web of Science ®Google Scholar
• Mao JS, Chai SA, Xie RY, Chen NL, Jiang Q, Zhu XZ, Zhang SY, Huang HY, Mao HW, Bao XN, et al. Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2-strain) in humans. Vaccine. 1997;15(9):944–47. doi:10.1016/S0264-410X(96)00304-0.
   PubMed Web of Science ®Google Scholar
• Ghildayal N. Cost-effectiveness of hepatitis A vaccination in a developed and developing country. Int J Health Care Qual Assur. 2019;32(8):1175–99. doi:10.1108/IJHCQA-05-2019-0096.
   PubMed Web of Science ®Google Scholar
• Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA. 2005;294(2):202–10. doi:10.1001/jama.294.2.202.
   PubMed Web of Science ®Google Scholar
• Souto FJD, de Brito WI, Fontes CJF. Impact of the single-dose universal mass vaccination strategy against hepatitis A in Brazil. Vaccine. 2019;37(6):771–75. doi:10.1016/j.vaccine.2018.12.054.
   PubMed Web of Science ®Google Scholar
• Dhankhar P, Nwankwo C, Pillsbury M, Lauschke A, Goveia MG, Acosta CJ, Elbasha EH. Public health impact and cost-effectiveness of hepatitis A vaccination in the United States: a disease transmission dynamic modeling approach. Value Health. 2015;18(4):358–67. doi:10.1016/j.jval.2015.02.004.
   PubMed Web of Science ®Google Scholar
• Sartori AM, de Soarez PC, Novaes HM, Amaku M, de Azevedo RS, Moreira RC, Pereira LM, Ximenes RA, Martelli CM. Cost-effectiveness analysis of universal childhood hepatitis A vaccination in Brazil: regional analyses according to the endemic context. Vaccine. 2012;30(52):7489–97. doi:10.1016/j.vaccine.2012.10.056.
   PubMed Web of Science ®Google Scholar
• Lopez E, Debbag R, Coudeville L, Baron-Papillon F, Armoni J. The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis. J Gastroenterol. 2007;42(2):152–60. doi:10.1007/s00535-006-1984-x.
   PubMed Web of Science ®Google Scholar
• Chironna M, Prato R, Sallustio A, Martinelli D, Tafuri S, Quarto M, Germinario C. Hepatitis A in Puglia (South Italy) after 10 years of universal vaccination: need for strict monitoring and catch-up vaccination. BMC Infect Dis. 2012;12(1):271. doi:10.1186/1471-2334-12-271.
   PubMedGoogle Scholar
• Doshani M, Weng M, Moore KL, Romero JR, Nelson NP. Recommendations of the Advisory Committee on immunization practices for use of hepatitis A vaccine for persons experiencing homelessness. MMWR Morb Mortal Wkly Rep. 2019;68(6):153–56. doi:10.15585/mmwr.mm6806a6.
   PubMed Web of Science ®Google Scholar
• O’Leary ST, Maldonado YA, Kimberlin DW. Update from the Advisory Committee on immunization practices. J Pediatric Infect Dis Soc. 2019;8(5):379–83. doi:10.1093/jpids/piz045.
   PubMed Web of Science ®Google Scholar
• Rowe IA, Parker R, Armstrong MJ, Houlihan DD, Mutimer DJ. Hepatitis A virus vaccination in persons with hepatitis C virus infection: consequences of quality measure implementation. Hepatology. 2012;56(2):501–06. doi:10.1002/hep.25683.
   PubMed Web of Science ®Google Scholar
• Freeman E, Lawrence G, McAnulty J, Tobin S, MacIntyre CR, Torvaldsen S. Field effectiveness of hepatitis A vaccine and uptake of post exposure prophylaxis following a change to the Australian guidelines. Vaccine. 2014;32(42):5509–13. doi:10.1016/j.vaccine.2014.07.048.
   PubMed Web of Science ®Google Scholar
• The LTatHAGGGf, from: PaCoHAIcA. http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1259152095231
   Google Scholar
• Ministry of Health – Israel. Guidelines for vaccination. Department of Epidemiology e; 2015.
   Google Scholar
• Vacchino MN. Incidence of hepatitis A in Argentina after vaccination. J Viral Hepat. 2008;15 Suppl 2:47–50. doi:10.1111/j.1365-2893.2008.01029.x.
   PubMed Web of Science ®Google Scholar
• Daniels D, Grytdal S, Wasley A, Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ. 2009;58(3):1–27.
   PubMedGoogle Scholar
• Seo JY, Choi S, Choi B, Ki M. Age-period-cohort analysis of hepatitis A incidence rates in Korea from 2002 to 2012. Epidemiol Health. 2016;38:e2016040. doi:10.4178/epih.e2016040.
   PubMed Web of Science ®Google Scholar
• Hu X, Collier MG, Xu F. Hepatitis A outbreaks in developed countries: detection, control, and prevention. Foodborne Pathog Dis. 2019.
   Web of Science ®Google Scholar
• Ki M, Son H, Choi BY. Causes and countermeasures for repeated outbreaks of hepatitis A among adults in Korea. Epidemiol Health. 2019;41:e2019038. doi:10.4178/epih.e2019038.
   PubMed Web of Science ®Google Scholar
• Ki M; Hepatitis Research Team. Economic analysis of vaccination and development of guidelines for control of hepatitis A virus infection aeaadocsoh.
   Google Scholar
• Kader C, Gocmen AY, Demir MI, Colak NY, Gok SE, Arkan FI, Sara MY, Erbay A. Hepatitis A immunity in Yozgat, Turkey. Ann Saudi Med. 2019;39(1):37–41. doi:10.5144/0256-4947.2019.37.
   PubMed Web of Science ®Google Scholar
• Enkirch T, Eriksson R, Persson S, Schmid D, Aberle SW, Lof E, Wittesjo B, Holmgren B, Johnzon C, Gustafsson EX, et al. Hepatitis A outbreak linked to imported frozen strawberries by sequencing, Sweden and Austria, June to September 2018. Euro Surveill. 2018;23(41).
   PubMedGoogle Scholar
• Viray MA, Hofmeister MG, Johnston DI, Krishnasamy VP, Nichols C, Foster MA, Balajadia R, Wise ME, Manuzak A, Lin Y, et al. Public health investigation and response to a hepatitis A outbreak from imported scallops consumed raw-Hawaii, 2016. Epidemiol Infect. 2018:1–8.
   PubMed Web of Science ®Google Scholar
• Mollers M, Boxman ILA, Vennema H, Slegers-Fitz-James IA, Brandwagt D, Friesema IH, Batstra JS, Te Wierik MJM. Successful use of advertisement pictures to assist recall in a food-borne hepatitis A outbreak in the Netherlands, 2017. Food Environ Virol. 2018;10(3):272–77. doi:10.1007/s12560-018-9347-3.
   PubMed Web of Science ®Google Scholar
• Plunkett J, Mandal S, Balogun K, Beebeejaun K, Ngui SL, Ramsay M, Edelstein M. Hepatitis A outbreak among men who have sex with men (MSM) in England, 2016–2018: the contribution of past and current vaccination policy and practice. Vaccine X. 2019;1:100014.
   PubMedGoogle Scholar
• Mariojoules J, Castro G, Pisano MB, Barbero P, Fantilli A, Borda M, Canna F, Barbas G, Re V. Hepatitis A outbreak affecting men who have sex with men (MSM) in central Argentina, occurred in July 2017–April 2018, later than the European outbreak. J Clin Virol. 2019;117:49–53. doi:10.1016/j.jcv.2019.05.014.
   PubMed Web of Science ®Google Scholar
• Mauro MV, Greco F, Tenuta R, Apuzzo G, Costantino A, Bruni R, Equestre M, Ciccaglione AR, Giraldi C, Mastroianni A. Hepatitis A outbreak affecting men who have sex with men (MSM) in South Italy. New Microbiol. 2019;42:181–83.
   PubMed Web of Science ®Google Scholar
• Wilson E, Hofmeister MG, McBee S, Briscoe J, Thomasson E, Olaisen RH, Augustine R, Duncan E, Bamrah Morris S, Haddy L. Notes from the field: hepatitis A outbreak associated with drug use and homelessness - West Virginia, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(14):330–31. doi:10.15585/mmwr.mm6814a4.
   PubMed Web of Science ®Google Scholar
• Yoshimura Y, Horiuchi H, Sawaki K, Miyata N, Kumazaki M, Usuku S, Tachikawa N. Hepatitis A outbreak among men who have sex with men, Yokohama, Japan, January to May 2018. Sex Transm Dis. 2019;46(3):e26–27. doi:10.1097/OLQ.0000000000000937.
   PubMed Web of Science ®Google Scholar
• Friesema IH, Sonder GJ, Petrignani MW, Meiberg AE, van Rijckevorsel GG, Ruijs WL, Vennema H. Spillover of a hepatitis A outbreak among men who have sex with men (MSM) to the general population, the Netherlands, 2017. Euro Surveill. 2018;23(23).
   Google Scholar